Patients diagnosed with advanced/metastatic HER2-negative breast cancer with confirmed metastatic disease, regardless of being de novo diagnosed or progressed from a non-metastatic stage.
Patients who are planned to receive anti-TROP2 antibody-drug conjugate (ADC) therapy (e.g., sacituzumab govitecan or datopotamab deruxtecan) as part of routine clinical care.
Patients who will undergo protocol-defined \^68Ga-TROP2 PET/CT and \^18F-FDG PET/CT during the study (baseline imaging, with repeat imaging per protocol if applicable).
Adult patients (≥18 years) who are able to provide informed consent and comply with study procedures.
You may not be if
Patients with incomplete medical records or inability to complete the required imaging assessments.
Patients with prior exposure to an anti-TROP2 ADC.
Patients with known contraindications to PET/CT or known allergy to \^18F-FDG or the \^68Ga-TROP2 tracer (or their components).
Patients who are pregnant or breastfeeding.
Patients diagnosed with secondary primary tumors (other active malignancies), as determined by the investigator.
Clareo Health | Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer
